UNITY Expands Human Senolytic Trial
UNITY Biotechnologies announced recently that it would be expanding its first-stage clinical trial in humans of UBX0101. This drug has shown senolytic effects in mice [1]; the company is hopeful that this drug will help treat painful osteoarthritis in the knee.
A clinical trial with an expanded scope
UNITY Biotechnologies (UBX0101), a $495-million biotech company that is developing senolytic drugs to target one of aging’s processes, announced the expansion of its first stage human trial.
Source:
https://www.leafscience.org/unity-expands-human-senolytic-trial/
